Q: Could you comment on today's news release. There seems to be strong growth in patient visits and practitioners but is this at the expense of growing revenues and ultimately profits?
Q: What is wrong with this stock? It keeps going down regardless of market direction. Hits 52 weeks low today. Is it time to bail out of this?
Thank you
Q: Do you have any insight to the reason for the big drop in TMO"s share price today. As well what are your overall thoughts on this company. Thank You.
Q: Can you recommend one or more etf's that would provide exposure to the health industry including medical devices, genomics, biotech, big pharma etc. Covered call etf's in these sectors would also be of interest. Thanks
Q: In a question today regarding top health care stocks you mentioned abbivie as one of the top choices but not lly. I know that in the recent past you were strong on lly over abbevie. I bought lly at that time, in fact, and profited quite well from the purchase. Thank you. My question is what made you pinpoint lly as a good prospect earlier on and what brings you to not mention it now in response to the question on top health care stocks?
Q: It seems many analysts feel that Health care is a good place to be going into the next 1 to 2 years, do you agree?
Could you name your top 5 Health Care Names, Canada or US?
Q: Based on your last comments on Pliant therapeutics(PLRX) from May 12, could you please update on those specific comments and on the recent news that made the stock double. Where do you see it going from here? This is what you wrote last time…
Asked by James on May 12, 2021
5I RESEARCH ANSWER:
PLRX has $277M in cash, but only expected revenue of $16M this year. Cash burn was $37M in 2020. 1Q loss of 64 cents per share was 6% worse than estimates; sales of $2.2M were 49% worse than expected. Insiders own 3.5% directly. We do not know management but see no concerns there. There is not much to go on here. As a clinical stage company, performance is going to depend on trial results. It has two main trials (early stage) that will be releasing results later this year. The pipeline is decent but again, early stage. It has been public less than a year, but shares have nearly doubled in that time. There is upside potential for sure, but the future may also be binary based on good/bad trial results.
Wondering if TXF is beaten down enough to provide a good entry point. Is there a better ETF for similar exposure in CAD?
What are 5i's thoughts on HHL for weathering the next year or two with possible recession and general market uncertainties? I expect healthcare may see less volatility but would like your perspective, please.
Q: Hi 5i
Just read an article about ‘ synthetic biology’
Sounds interesting. Do you know anything about the industry? If so do you see any companies that look of interest.
Thx
Gerry
Q: Dear 5i,
Do you like DHR and/or TMO for a long term buy and forget stock?
If yes, which would you prefer one or both?
Is there much overlap between these two stocks?
Q: I am considering investment in HHL primarily for the Dividend but it has also pulled back in this market, so potential growth as well. Is Healthcare and Dividend ETF's fairly safe in this current market? Is there another ETF with good income and some potential for growth. Thanks